NVO vs. LLY, JNJ, MRK, ABBV, AZN, NVS, ABT, PFE, UNH, and TMO
Should you be buying Novo Nordisk A/S stock or one of its competitors? The main competitors of Novo Nordisk A/S include Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), AbbVie (ABBV), AstraZeneca (AZN), Novartis (NVS), Abbott Laboratories (ABT), Pfizer (PFE), UnitedHealth Group (UNH), and Thermo Fisher Scientific (TMO). These companies are all part of the "medical" sector.
Novo Nordisk A/S (NYSE:NVO) and Eli Lilly and Company (NYSE:LLY) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.
11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by company insiders. Comparatively, 0.1% of Eli Lilly and Company shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Novo Nordisk A/S has higher earnings, but lower revenue than Eli Lilly and Company. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.
Novo Nordisk A/S has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, Eli Lilly and Company has a beta of 0.34, meaning that its stock price is 66% less volatile than the S&P 500.
Novo Nordisk A/S has a net margin of 36.03% compared to Eli Lilly and Company's net margin of 15.36%. Novo Nordisk A/S's return on equity of 90.36% beat Eli Lilly and Company's return on equity.
Novo Nordisk A/S currently has a consensus target price of $133.60, suggesting a potential upside of 8.84%. Eli Lilly and Company has a consensus target price of $728.05, suggesting a potential downside of 2.40%. Given Novo Nordisk A/S's higher probable upside, equities analysts plainly believe Novo Nordisk A/S is more favorable than Eli Lilly and Company.
Eli Lilly and Company received 765 more outperform votes than Novo Nordisk A/S when rated by MarketBeat users. Likewise, 69.98% of users gave Eli Lilly and Company an outperform vote while only 60.60% of users gave Novo Nordisk A/S an outperform vote.
In the previous week, Eli Lilly and Company had 39 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 72 mentions for Eli Lilly and Company and 33 mentions for Novo Nordisk A/S. Novo Nordisk A/S's average media sentiment score of 0.49 beat Eli Lilly and Company's score of 0.41 indicating that Novo Nordisk A/S is being referred to more favorably in the media.
Novo Nordisk A/S pays an annual dividend of $1.33 per share and has a dividend yield of 1.1%. Eli Lilly and Company pays an annual dividend of $5.20 per share and has a dividend yield of 0.7%. Novo Nordisk A/S pays out 49.2% of its earnings in the form of a dividend. Eli Lilly and Company pays out 89.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.
Summary
Eli Lilly and Company beats Novo Nordisk A/S on 11 of the 20 factors compared between the two stocks.
Get Novo Nordisk A/S News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Novo Nordisk A/S Competitors List
Related Companies and Tools
